BNB Plus Corp. (BNBX)
| Market Cap | 2.30M +129.6% |
| Revenue (ttm) | 1.83M -12.5% |
| Net Income | -70.57M |
| EPS | -44.63 |
| Shares Out | 5.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,527 |
| Open | 0.4000 |
| Previous Close | 0.4098 |
| Day's Range | 0.3900 - 0.4250 |
| 52-Week Range | 0.3889 - 9.6760 |
| Beta | 0.56 |
| Analysts | Hold |
| Price Target | 22,499.99 (+5,554,767.3%) |
| Earnings Date | May 15, 2026 |
About BNBX
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutica... [Read more]
Financial Performance
In fiscal year 2025, BNB Plus's revenue was $2.14 million, an increase of 1.11% compared to the previous year's $2.11 million. Losses were -$69.49 million, 861.7% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for BNBX stock is "Hold" and the 12-month stock price target is $22,499.99.
News
BNB Plus Quarterly report: Q2 2026
BNB Plus has published its Q2 2026 quarterly earnings report on May 15, 2026.
BNB Plus Transcript: EGM 2026
Stockholders approved granting the board authority for a reverse stock split at a ratio between 1-for-5 and 1-for-30, and also approved the adjournment proposal. Both measures passed with a majority of votes, and final results will be filed with the SEC.
BNB Plus ‘continues to execute’ on operating initiatives amid strategic review
As previously announced on April 20, 2026, the Company’s Board of Directors authorized a formal review of strategic alternatives to maximize shareholder value. The Company continues to execute on its…
BNB Plus Corp. completes production of $1.2M LineaDNA order
BNB Plus completed production of its largest order in LineaRx history. The $1.2M order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically…
BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has successfully completed pro...
BNB Plus Corp. announces review of strategic alternatives
BNB Plus’ Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update on its Nasdaq listing status. The strategic alternatives...
BNB Plus Corp. receives non-compliance notice from Nasdaq
On March 20, the Company received written notice from the Listing Qualifications Department of Nasdaq indicating that the Company no longer satisfies the minimum $1.00 bid price requirement for contin...
BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of...
BNB Plus Proxy statement: Proxy filing
BNB Plus filed a proxy statement on March 24, 2026, providing details for shareholder voting and corporate governance matters.
BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent...
BNB Plus Proxy statement: Proxy Filing
BNB Plus filed a proxy statement on March 12, 2026, providing details for shareholder voting and corporate governance matters.
BNB Plus Corp. reports BNB token holdings valued at $10.7M as of February 23
BNB Plus Corp. (BNBX) provided an update on its BNB (BNB-USD) token holdings and digital asset portfolio. The company maintains significant holdings of BNB tokens and OBNB trust units as…
BNB Plus Corp. receives two new orders for LineaDNA
BNB Plus Corp. (BNBX) announced that its biopharmaceutical subsidiary, LineaRx, has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment ...
BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for Lin...
BNB Plus Quarterly report: Q1 2026
BNB Plus has published its Q1 2026 quarterly earnings report on February 12, 2026.
BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Commit...
BNB Plus Transcript: Fintech & DATS Investor Conference
BNBX leverages four non-directional yield strategies on BNB to target 9%-12% annualized returns, combining long BNB exposure with compounding yield. The approach offers a unique way to access Binance’s growth and earnings, with robust risk management and operational transparency.
BNB Plus Transcript: Digital Asset Treasury Virtual Investor Conference
BNB Plus outlined its BNB-focused digital asset treasury strategy, leveraging unique yield opportunities and deflationary tokenomics to target 8%-12% annualized returns. The company has restructured its legacy DNA business for profitability and is exploring M&A to scale.
BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will pres...
BNB Plus Corp. receives $1.2M order for LineaDNA
BNB Plus Corp. (BNBX) announced that it has received a $1.2M order for LineaDNA, representing the largest LineaDNA order in company history. The order is an acceleration of an existing…
BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Comp...
BNB Plus Registration statement: Registration Filing
BNB Plus filed a registration statement on December 22, 2025, providing details about a securities offering with the SEC.
BNB Plus Annual report: Q4 2025
BNB Plus has published its Q4 2025 annual report on December 21, 2025.
BNB Plus Corp. ships largest single LineaDNA order
BNB Plus Corp. (BNBX) announced that it has manufactured and shipped the largest single LineaDNA order in company history, valued at over $390,000. The approximately five-gram shipment, manufactured b...
BNB Plus Corp. (BNBX) Announces Largest Ever Shipment of LineaDNATM
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has successfully manufactured and shipped the largest single LineaDNA order in Company histo...